DrugPatentWatch Database Preview
Drugs in Development Information for D-Tryptophan
» See Plans and Pricing
What is the development status for investigational drug D-Tryptophan?
D-Tryptophan is an investigational drug.
There have been 16 clinical trials for D-Tryptophan.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 10th 2020.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Breast Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), NewLink Genetics Corporation, and H. Lee Moffitt Cancer Center and Research Institute.
Summary for D-Tryptophan
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,297 |
| WIPO Patent Applications | 2,428 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 1 (2020-12-10) |
| Vendors | 89 |
Recent Clinical Trials for D-Tryptophan
| Title | Sponsor | Phase |
|---|---|---|
| Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery | Advanced Accelerator Applications | Phase 1 |
| Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery | Stanford University | Phase 1 |
| Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study | National Cancer Institute (NCI) | Phase 3 |
Clinical Trial Summary for D-Tryptophan
Top disease conditions for D-Tryptophan
Top clinical trial sponsors for D-Tryptophan
US Patents for D-Tryptophan
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
